Targeting the inhibitory immune microenvironment to overcome T cell exhaustion with anti-CTLA4 and anti-PD-1/PD-L1 checkpoint inhibitors has proven effective for solid tumors2,3 but barely for leukemias, although AML patients present with CD8 exhaustion signatures4–6. The gene discussed is CD8A; the disease is leukemia.